



## **BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference**

May 31, 2019

NEW HAVEN, Conn., May 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Jefferies 2019 Global Healthcare Conference being held June 4 – 7, 2019 in New York City.

Details of the Conference:

Event: Jefferies Global Healthcare Conference

Date: June 7, 2019

Time: 9:00 – 9:25 AM ET

In addition to his presentation, Dr. Mehta will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with BTI management should contact their Jefferies representative. A live webcast of the presentation will be accessible through the Investors section of the company's website at [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com). Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for 30 days.

### **About BioXcel Therapeutics, Inc.:**

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance next wave of medicines in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit [www.bioxccltherapeutics.com](http://www.bioxccltherapeutics.com).

### **Contact Information:**

BioXcel Therapeutics  
The Ruth Group  
Janhavi Mohite  
646-536-7026  
[jmohite@theruthgroup.com](mailto:jmohite@theruthgroup.com)

Source: BioXcel Therapeutics, Inc.